

Efficiency of GelX in Treating Oral Mucositis in a Patient

Belfast Health and Social Care Trust



Patient background

- 36 year old male.
- History of Lymphoma.

Treatment regime:

Obinatumab and Bendamustine. Last treated August 2023 – ongoing ulceration/mucositis post treatment non healing. Regular clinic appointments; admission due to same – AKI/ LFTs deranged and patient having difficulties eating and drinking secondary to pain.

Impact of ulceration

- Low Mood.
- Poor nutritional/fluid intake due to pain.
- Poor sleep.
- Difficulties speaking.
- Admission for hydration and bloods review.
- Socially isolated as pain and ulceration appearance was impacting his ability to partake in conversations with others.

Treatments used for mouthcare

Nystatin®; GelClair®; Biotène®; paracetamol regularly; oxetecaine and previously chlorhexidine. Also using Bonjela®. Standard treatments and other oral mucositis treatments did not provide adequate relief for this patient.

Grading of ulceration pre GelX

Grade 2 and grade 3. Grade 2 to throat and Grade 3 to gums/lips.

24 hours after starting GelX

- Significant improvement to ulceration.
- Grade 3 ulceration now Grade 2 and Grade 2 ulceration now Grade 1.
- Quality of life improvements: full nights sleep; eating and drinking well; smiling and reporting an overall mood improvement.

Within 48 hours

- Grade 3 ulceration now Grade 1, and all other ulceration gone.
- Patient discharged home – previous plan was admit for 7 days potentially longer.
- Patient discharged within 72 hours of admission and 36 hours of commencing GelX.

Findings

- Notable improvement within a short time period.
- Single agent therapy more cost effective than multiple therapy lines.
- Shorter hospital admission.
- Improvement in patient mood.

Patient feedback:

The taste is more tolerable than current standard treatment. "Something has FINALLY worked!! Looking forward to Christmas Dinner now!!!"